BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013;37:1132-1156. [PMID: 23638982 DOI: 10.1111/apt.12324] [Cited by in Crossref: 108] [Cited by in F6Publishing: 87] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Serigado JM, Barboza KC, Marcus P, Sigal SH. Clinical Impact of Depression in Cirrhosis. Curr Hepatology Rep 2018;17:22-32. [DOI: 10.1007/s11901-018-0386-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Johnson AL, Hayward KL. Managing medicines in alcohol-associated liver disease: a practical review. Aust Prescr 2021;44:96-106. [PMID: 34211248 DOI: 10.18773/austprescr.2021.015] [Reference Citation Analysis]
3 Hilscher MB, Odell LJ, Myhre LJ, Prokop L, Talwalkar J. The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions. J Clin Pharm Ther 2016;41:587-91. [PMID: 27576303 DOI: 10.1111/jcpt.12443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Haque T, Sasatomi E, Hayashi PH. Drug-Induced Liver Injury: Pattern Recognition and Future Directions. Gut Liver 2016;10:27-36. [PMID: 26696029 DOI: 10.5009/gnl15114] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
5 Gadour E, Kotb A. Systematic Review of Antifungal-Induced Acute Liver Failure. Cureus 2021;13:e18940. [PMID: 34703680 DOI: 10.7759/cureus.18940] [Reference Citation Analysis]
6 Howard M, Barber J, Alizai N, Rostami-Hodjegan A. Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics. Expert Opin Drug Metab Toxicol 2018;14:1315-30. [PMID: 30465453 DOI: 10.1080/17425255.2018.1546288] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Waterman BL, Ramsey SU, Whitsett MP, Patel AA, Radcliff JA, Kotler DL, Winters AC, Woodrell CD, Ufere NN, Serper M, Walling AM, Jones CA, Kelly SG. Top Ten Tips Palliative Care Clinicians Should Know About End-Stage Liver Disease. J Palliat Med 2021;24:924-31. [PMID: 33733875 DOI: 10.1089/jpm.2021.0097] [Reference Citation Analysis]
8 Zuccaro V, Columpsi P, Sacchi P, Lucà MG, Fagiuoli S, Bruno R. Antibiotic stewardship and empirical antibiotic treatment: How can they get along? Digestive and Liver Disease 2017;49:579-84. [DOI: 10.1016/j.dld.2017.01.157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
9 Evers R, Piquette-Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, Ware JA, de Wildt SN, Xie W, Brouwer KLR; International Transporter Consortium. Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clin Pharmacol Ther 2018;104:900-15. [PMID: 29756222 DOI: 10.1002/cpt.1115] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
10 Zgheib NK, Branch RA. Drug metabolism and liver disease: a drug-gene-environment interaction. Drug Metab Rev 2017;49:35-55. [PMID: 27957864 DOI: 10.1080/03602532.2016.1271807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Pena M, Horga J, Zapater P. Variations of pharmacokinetics of drugs in patients with cirrhosis. Expert Review of Clinical Pharmacology 2015;9:441-58. [DOI: 10.1586/17512433.2016.1135733] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
12 Ogedengbe OO, Naidu ECS, Azu OO. Antiretroviral Therapy and Alcohol Interactions: X-raying Testicular and Seminal Parameters Under the HAART Era. Eur J Drug Metab Pharmacokinet 2018;43:121-35. [DOI: 10.1007/s13318-017-0438-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Picardi A, Vespasiani-Gentilucci U. Proton pump inhibitor prescription abuse and sepsis in cirrhosis. World J Gastrointest Pharmacol Ther 2016; 7(1): 1-4 [PMID: 26855807 DOI: 10.4292/wjgpt.v7.i1.1] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
14 Lewis JH. The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond. Clin Gastroenterol Hepatol. 2015;13:2173-2189.e8. [PMID: 26116527 DOI: 10.1016/j.cgh.2015.06.017] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
15 Zoratti C, Moretti R, Rebuzzi L, Albergati IV, Di Somma A, Decorti G, Di Bella S, Crocè LS, Giuffrè M. Antibiotics and Liver Cirrhosis: What the Physicians Need to Know. Antibiotics (Basel) 2021;11:31. [PMID: 35052907 DOI: 10.3390/antibiotics11010031] [Reference Citation Analysis]
16 Zhang M, Xu X, Liu W, Zhang Z, Cheng Q, Yang Z, Liu T, Liu Y, Ning Q, Chen T, Qi J. Proton Pump Inhibitor Therapy Increases the Risk of Spontaneous Bacterial Peritonitis in Patients with HBV-Related Acute-on-Chronic Liver Failure. Adv Ther 2021;38:4675-94. [PMID: 34308513 DOI: 10.1007/s12325-021-01844-1] [Reference Citation Analysis]
17 O'Leary JG, Tandon P, Reddy KR, Biggins SW, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Lai J, Fallon M, Vargas HE, Thuluvath P, Subramanian R, Thacker LR, Bajaj JS. Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. Dig Dis Sci 2020;65:2571-9. [PMID: 32146602 DOI: 10.1007/s10620-020-06168-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Cheema E, Al-Aryan A, Al-Hamid A. Medicine use and medicine-related problems in patients with liver cirrhosis: a systematic review of quantitative and qualitative studies. Eur J Clin Pharmacol 2019;75:1047-58. [PMID: 31079169 DOI: 10.1007/s00228-019-02688-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
19 Stine JG, Lewis JH. Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis. 2013;17:609-642, ix. [PMID: 24099021 DOI: 10.1016/j.cld.2013.07.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
20 Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, Saigal S, Saraf N, Soin AS, Devarbhavi H, Kim DJ, Dhiman RK, Duseja A, Taneja S, Eapen CE, Goel A, Ning Q, Chen T, Ma K, Duan Z, Yu C, Treeprasertsuk S, Hamid SS, Butt AS, Jafri W, Shukla A, Saraswat V, Tan SS, Sood A, Midha V, Goyal O, Ghazinyan H, Arora A, Hu J, Sahu M, Rao PN, Lee GH, Lim SG, Lesmana LA, Lesmana CR, Shah S, Prasad VGM, Payawal DA, Abbas Z, Dokmeci AK, Sollano JD, Carpio G, Shresta A, Lau GK, Fazal Karim M, Shiha G, Gani R, Kalista KF, Yuen MF, Alam S, Khanna R, Sood V, Lal BB, Pamecha V, Jindal A, Rajan V, Arora V, Yokosuka O, Niriella MA, Li H, Qi X, Tanaka A, Mochida S, Chaudhuri DR, Gane E, Win KM, Chen WT, Rela M, Kapoor D, Rastogi A, Kale P, Sharma CB, Bajpai M, Singh V, Premkumar M, Maharashi S, Olithselvan A, Philips CA, Srivastava A, Yachha SK, Wani ZA, Thapa BR, Saraya A, Shalimar, Kumar A, Wadhawan M, Gupta S, Madan K, Sakhuja P, Vij V, Sharma BC, Garg H, Garg V, Kalal C, Anand L, Vyas T, Mathur RP, Kumar G, Jain P, Pasupuleti SSR, Chawla YK, Chowdhury A, Song DS, Yang JM, Yoon EL;  APASL ACLF Research Consortium (AARC) for APASL ACLF working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:353-390. [PMID: 31172417 DOI: 10.1007/s12072-019-09946-3] [Cited by in Crossref: 134] [Cited by in F6Publishing: 109] [Article Influence: 44.7] [Reference Citation Analysis]
21 Britnell SR, Willets AE, Vanderman AJ, Woodard CL, Britt RB. Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans. Pharmacotherapy 2016;36:1173-9. [PMID: 27716978 DOI: 10.1002/phar.1845] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Webster CRL, Center SA, Cullen JM, Penninck DG, Richter KP, Twedt DC, Watson PJ. ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs. J Vet Intern Med 2019;33:1173-200. [PMID: 30844094 DOI: 10.1111/jvim.15467] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
23 Stine JG, Wang J, Behm BW. Chronic Cholestatic Liver Injury Attributable to Vedolizumab. J Clin Transl Hepatol. 2016;4:277-280. [PMID: 27777897 DOI: 10.14218/jcth.2016.00018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Chalhoub WM, Sliman KD, Arumuganathan M, Lewis JH. Drug-induced liver injury: what was new in 2013? Expert Opin Drug Metab Toxicol. 2014;10:959-980. [PMID: 24746272 DOI: 10.1517/17425255.2014.909408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
25 Stine JG, Chalasani NP. Drug Hepatotoxicity: Environmental Factors. Clin Liver Dis. 2017;21:103-113. [PMID: 27842766 DOI: 10.1016/j.cld.2016.08.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
26 Tong HY, Medrano N, Borobia AM, Martínez AM, Martín J, Ruiz JA, García S, Quintana M, Carcas AJ, Frías J, Ramírez E. Hepatotoxicity induced by acute and chronic paracetamol overdose in adults. Where do we stand? Regul Toxicol Pharmacol 2015;72:370-8. [PMID: 25985715 DOI: 10.1016/j.yrtph.2015.05.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
27 Shahbaz O, Mahajan S, Lewis JH. Highlights of Drug - and Herb- induced liver injury in the Literature from 2016: How Best to Translate New Information into Clinical Practice? Expert Opin Drug Metab Toxicol. 2017;13:935-951. [PMID: 28772086 DOI: 10.1080/17425255.2017.1362391] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
28 Weersink RA, Burger DM, Hayward KL, Taxis K, Drenth JP, Borgsteede SD. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations. Expert Opinion on Drug Metabolism & Toxicology 2020;16:45-57. [DOI: 10.1080/17425255.2020.1702022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
29 Stine JG, Intagliata N, Shah NL, Argo CK, Caldwell SH, Lewis JH, Northup PG. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci. 2015;60:1031-1035. [PMID: 25373453 DOI: 10.1007/s10620-014-3422-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
30 Palmer M, Regev A, Lindor K, Avigan MI, Dimick-Santos L, Treem W, Marcinak JF, Lewis JH, Anania FA, Seekins D, Shneider BL, Chalasani N. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther. 2020;51:90-109. [PMID: 31762074 DOI: 10.1111/apt.15579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
31 Ephros H, Shah S, Herrod RJ. A Review of Sedation Agents. Oral Maxillofac Surg Clin North Am 2022;34:21-34. [PMID: 34696971 DOI: 10.1016/j.coms.2021.09.001] [Reference Citation Analysis]
32 Torres HA, McDonald GB. How I treat hepatitis C virus infection in patients with hematologic malignancies. Blood 2016;128:1449-57. [PMID: 27443290 DOI: 10.1182/blood-2016-05-718643] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
33 Lee V, Goyal A, Hsu CC, Jacobson JS, Rodriguez RD, Siegel AB. Dietary supplement use among patients with hepatocellular carcinoma. Integr Cancer Ther 2015;14:35-41. [PMID: 25228537 DOI: 10.1177/1534735414550038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
34 Hoppmann NA, Gray ME, McGuire BM. Drug-Induced Liver Injury in the Setting of Chronic Liver Disease. Clin Liver Dis 2020;24:89-106. [PMID: 31753253 DOI: 10.1016/j.cld.2019.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749-1761. [PMID: 24480518 DOI: 10.1016/s0140-6736(14)60121-5] [Cited by in Crossref: 801] [Cited by in F6Publishing: 395] [Article Influence: 100.1] [Reference Citation Analysis]
36 Kumar M, Panda D. Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma. Journal of Clinical and Experimental Hepatology 2014;4:S130-9. [DOI: 10.1016/j.jceh.2014.03.049] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
37 Weersink RA, Bouma M, Burger DM, Drenth JP, Hunfeld NG, Kranenborg M, Monster-Simons MH, van Putten SA, Metselaar HJ, Taxis K, Borgsteede SD. Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. BMJ Open 2016;6:e012991. [PMID: 27733414 DOI: 10.1136/bmjopen-2016-012991] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
38 Devarbhavi H, Choudhury AK, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, Chawla YK, Dhiman RK, Duseja A, Taneja S, Ning Q, Jia JD, Duan Z, Yu C, Eapen CE, Goel A, Tan SS, Hamid SS, Butt AS, Jafri W, Kim DJ, Hu J, Sood A, Midha V, Shukla A, Ghazinian H, Sahu MK, Treeprasertsuk S, Lee GH, Lim SG, Lesmana LA, Lesmana CR, Shah S, Kalal C, Abbas Z, Sollano JD, Prasad VGM, Payawal DA, Dokmeci AK, Rao PN, Shrestha A, Lau GK, Yuen MF, Saraswat VA, Shiha G, Yokosuka O, Kedarisetty CK, Jain P, Bhatia P, Sarin SK; APASL ACLF working party. Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients. Am J Gastroenterol. 2019;114:929-937. [PMID: 31021832 DOI: 10.14309/ajg.0000000000000201] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
39 Mo Z, Lei Z, Wang P, Wu Z, Yuan H, Xie D, Wu Z, Huang Z. Hepatotoxicity of iodine-131 ablation for post-surgical differentiated thyroid cancer patients with hepatitis B virus infection. Clin Res Hepatol Gastroenterol 2021;45:101631. [PMID: 33662775 DOI: 10.1016/j.clinre.2021.101631] [Reference Citation Analysis]
40 Lewis JH. Causality assessment: which is best-expert opinion or RUCAM? Clinical Liver Dis. 2014;4:4-8. [PMID: 30992910 DOI: 10.1002/cld.365] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
41 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications. Clin Mol Hepatol 2018;24:230-77. [PMID: 29991196 DOI: 10.3350/cmh.2018.1005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
42 Ferreira V, Vincelette C, Mathieu A. Joint Efforts to Ensure Evidence-Based Decisions by Clinicians in Drug Adjustment for Chronic Liver Disease Populations. Hepatol Commun 2021;5:713-4. [PMID: 33860128 DOI: 10.1002/hep4.1664] [Reference Citation Analysis]
43 Talima S, Kassem H, Kassem N. Chemotherapy and targeted therapy for breast cancer patients with hepatitis C virus infection.Breast Cancer. 2019;26:154-163. [PMID: 30191397 DOI: 10.1007/s12282-018-0904-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
44 Strein M, Holton-Burke JP, Smith LR, Brophy GM. Prevention, Treatment, and Monitoring of Seizures in the Intensive Care Unit. J Clin Med 2019;8:E1177. [PMID: 31394791 DOI: 10.3390/jcm8081177] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
45 Agbalajobi OM, Gmelin T, Moon AM, Alexandre W, Zhang G, Gellad WF, Jonassaint N, Rogal SS. Characteristics of opioid prescribing to outpatients with chronic liver diseases: A call for action. PLoS One 2021;16:e0261377. [PMID: 34919585 DOI: 10.1371/journal.pone.0261377] [Reference Citation Analysis]
46 Fediak I, Maksymenko O. ASSESSMENT OF THE FREQUENCY AND RATIONALITY OF PRESCRIBED MEDICINES IN PATIENTS WITH LIVER CIRRHOSIS. Eureka: HS 2021. [DOI: 10.21303/2504-5679.2021.001599] [Reference Citation Analysis]
47 Dotters-Katz SK, Kuller JA, Hughes BL; Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in pregnancy-updated guidelines: Replaces Consult Number 43, November 2017. Am J Obstet Gynecol 2021;225:B8-B18. [PMID: 34116035 DOI: 10.1016/j.ajog.2021.06.008] [Reference Citation Analysis]
48 Steelandt J, Jean-Bart E, Goutelle S, Tod M. A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification. Clin Pharmacokinet 2015;54:1245-58. [PMID: 26070946 DOI: 10.1007/s40262-015-0288-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
49 Gebreselassie A, Aduli F, Howell CD. Rheumatologic Diseases and the Liver. Clinics in Liver Disease 2019;23:247-61. [DOI: 10.1016/j.cld.2018.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Gross M. Wenn die Leber den Dienst versagt. MMW - Fortschritte der Medizin 2015;157:75-80. [DOI: 10.1007/s15006-015-2550-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
51 Kim M, Dam A, Green J. Common GI Drug Interactions in the Elderly. Curr Treat Options Gastroenterol 2014;12:292-309. [PMID: 25031070 DOI: 10.1007/s11938-014-0024-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
52 Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment Pharmacol Ther. 2014;40:880-892. [PMID: 25175904 DOI: 10.1111/apt.12925] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
53 Rodríguez Martínez S, Talaván Serna J, Silvestre FJ. [Dental management in patients with cirrhosis]. Gastroenterol Hepatol 2016;39:224-32. [PMID: 26541210 DOI: 10.1016/j.gastrohep.2015.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
54 Christian-Miller N, Frenette C. Hepatocellular cancer pain: impact and management challenges. J Hepatocell Carcinoma 2018;5:75-80. [PMID: 30050880 DOI: 10.2147/JHC.S145450] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol 2021;116:878-98. [PMID: 33929376 DOI: 10.14309/ajg.0000000000001259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
56 Society for Maternal-Fetal Medicine (SMFM), Hughes BL, Page CM, Kuller JA. Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol. 2017;217:B2-B12. [PMID: 28782502 DOI: 10.1016/j.ajog.2017.07.039] [Cited by in Crossref: 88] [Cited by in F6Publishing: 80] [Article Influence: 17.6] [Reference Citation Analysis]
57 Raschi E, Mazzotti A, Poluzzi E, De Ponti F, Marchesini G. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opin Pharmacother 2018;19:1903-14. [PMID: 30299993 DOI: 10.1080/14656566.2018.1531126] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
58 Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659 [PMID: 27678348 DOI: 10.3748/wjg.v22.i34.7645] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 72] [Article Influence: 12.0] [Reference Citation Analysis]
59 Papadopoulos N, Deutsch M, Georgalas A, Poulakidas H, Karnesis L. Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia. Case Rep Hematol 2016;2016:7635128. [PMID: 27042368 DOI: 10.1155/2016/7635128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
60 Hayward KL, Weersink RA. Improving Medication-Related Outcomes in Chronic Liver Disease. Hepatol Commun 2020;4:1562-77. [PMID: 33163829 DOI: 10.1002/hep4.1612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Saleh AAG, Sultan A, Hammouda MA, Shawki A, El Ghaffar MA. Value of Adding Dexmedetomidine in Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis for Treatment of Pancreatic Cancer-Associated Pain. J Gastrointest Cancer 2021;52:682-9. [PMID: 32621112 DOI: 10.1007/s12029-020-00449-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis. 2014;27:36-45. [PMID: 24305043 DOI: 10.1097/qco.0000000000000034] [Cited by in Crossref: 43] [Cited by in F6Publishing: 13] [Article Influence: 5.4] [Reference Citation Analysis]
63 Yamashita YI, Imai K, Mima K, Nakagawa S, Hashimoto D, Chikamoto A, Baba H. Idiosyncratic drug-induced liver injury: A short review. Hepatol Commun. 2017;1:494-500. [PMID: 29404475 DOI: 10.1002/hep4.1064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
64 Acharya C, Betrapally NS, Gillevet PM, Sterling RK, Akbarali H, White MB, Ganapathy D, Fagan A, Sikaroodi M, Bajaj JS. Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:319-31. [DOI: 10.1111/apt.13858] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 12.2] [Reference Citation Analysis]
65 Soleimanpour H, Parsian Z, Shahsavari Nia K, Rahmani F, Alavian SM. Which Dose of Acetaminophen is Safe in Cirrhotic Patients? Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.84767] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
66 Hamilton D, Nandkeolyar S, Lan H, Desai P, Evans J, Hauschild C, Choksi D, Abudayyeh I, Contractor T, Hilliard A. Amiodarone: A Comprehensive Guide for Clinicians. Am J Cardiovasc Drugs 2020;20:549-58. [DOI: 10.1007/s40256-020-00401-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
67 García-Cortés M, García-García A. Management of Pharmacologic Adverse Effects in Advanced Liver Disease. Clin Drug Investig 2022. [PMID: 35522395 DOI: 10.1007/s40261-022-01150-w] [Reference Citation Analysis]
68 Spernovasilis N, Kofteridis DP. Pre-Existing Liver Disease and Toxicity of Antifungals. J Fungi (Basel) 2018;4:E133. [PMID: 30544724 DOI: 10.3390/jof4040133] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
69 Aghili M, Neelathahalli Kasturirangan M. Identifying characteristics of drug-related problems in critically ill patients with decompensated liver cirrhosis. Eur J Gastroenterol Hepatol 2019;31:1569-76. [PMID: 31464786 DOI: 10.1097/MEG.0000000000001492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Ennis ZN, Dideriksen D, Vaegter HB, Handberg G, Pottegård A. Acetaminophen for Chronic Pain: A Systematic Review on Efficacy. Basic Clin Pharmacol Toxicol 2016;118:184-9. [DOI: 10.1111/bcpt.12527] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
71 Leone S, Rossi M, Bisi L, Gori A, Esposito S. Letter: antibiotic dose adjustment in patients with advanced liver disease. Aliment Pharmacol Ther. 2013;38:561-562. [PMID: 23937471 DOI: 10.1111/apt.12411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
72 Hamed AE. The association between diabetes and liver disease: The need for a consensus. Arab Journal of Gastroenterology 2014;15:166-8. [DOI: 10.1016/j.ajg.2014.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
73 Li X, Gan D, Li Y, Zhang P, Li Z, Du H, Zhang L, Cheng Y, Zhang Y, Liang Y, Ye Y. JianPi HuaZhuo XingNao formula (Chinese herbal medicine) for the treatment of minimal hepatic encephalopathy: a protocol for a randomized, placebo-controlled pilot trial. Medicine (Baltimore) 2018;97:e0526. [PMID: 29703024 DOI: 10.1097/MD.0000000000010526] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Halilovic J, Heintz BH. Antibiotic dosing in cirrhosis. American Journal of Health-System Pharmacy 2014;71:1621-34. [DOI: 10.2146/ajhp140031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
75 Pirmohamed M. Prescribing in liver disease. Medicine 2015;43:577-80. [DOI: 10.1016/j.mpmed.2015.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
76 Alempijevic T, Zec S, Milosavljevic T. Drug-induced liver injury: Do we know everything? World J Hepatol 2017; 9(10): 491-502 [PMID: 28443154 DOI: 10.4254/wjh.v9.i10.491] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 7.4] [Reference Citation Analysis]
77 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
78 Hayward KL, Patel PJ, Valery PC, Horsfall LU, Li CY, Wright PL, Tallis CJ, Stuart KA, Irvine KM, Cottrell WN, Martin JH, Powell EE. Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention. Hepatol Commun 2019;3:620-31. [PMID: 31061951 DOI: 10.1002/hep4.1334] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
79 Schwambach KH, Blatt CR. Effectiveness and potential drug interactions in antiviral therapy for the treatment of chronic hepatitis C: real-life data from a specialized center in southern Brazil. Braz J Pharm Sci 2021;57:e18746. [DOI: 10.1590/s2175-9790201900041874] [Reference Citation Analysis]
80 Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. American Journal of Gastroenterology 2014;109:950-66. [DOI: 10.1038/ajg.2014.131] [Cited by in Crossref: 408] [Cited by in F6Publishing: 344] [Article Influence: 51.0] [Reference Citation Analysis]
81 Hong YM, Yoon KT, Heo J, Woo HY, Lim W, An DS, Han JH, Cho M. The Prescription Pattern of Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs in Patients with Liver Cirrhosis. J Korean Med Sci 2016;31:1604-10. [PMID: 27550489 DOI: 10.3346/jkms.2016.31.10.1604] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
82 Mancuso A, Zavaglia C, Bai F, Puoti M, Belli LS. Letter: sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients. Aliment Pharmacol Ther 2013;38:1414-6. [DOI: 10.1111/apt.12536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
83 Tseng AS, Kowlgi GN, DeSimone CV. Antiarrhythmic Drugs for Atrial Fibrillation in the Outpatient Setting: Common Clinical Scenarios and Pearls for the Primary Care Clinician. Mayo Clin Proc 2021;96:2230-42. [PMID: 34119307 DOI: 10.1016/j.mayocp.2021.01.010] [Reference Citation Analysis]
84 Teschke R, Danan G. Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue? Expert Opin Drug Metab Toxicol. 2017;13:425-438. [PMID: 27822971 DOI: 10.1080/17425255.2017.1252749] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
85 Formentin C, Garrido M, Montagnese S. Assessment and Management of Sleep Disturbance in Cirrhosis. Curr Hepatol Rep 2018;17:52-69. [PMID: 29876197 DOI: 10.1007/s11901-018-0390-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
86 Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin. 2017;67:411-431. [PMID: 28683174 DOI: 10.3322/caac.21403] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
87 Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015;63:503-514. [PMID: 25912521 DOI: 10.1016/j.jhep.2015.04.016] [Cited by in Crossref: 200] [Cited by in F6Publishing: 175] [Article Influence: 28.6] [Reference Citation Analysis]
88 Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, Metselaar HJ, Monster-Simons MH, Taxis K, Borgsteede SD. Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis. Drug Saf 2018;41:603-13. [PMID: 29330714 DOI: 10.1007/s40264-017-0635-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
89 Malaguarnera G, Pennisi M, Bertino G, Motta M, Borzì AM, Vicari E, Bella R, Drago F, Malaguarnera M. Resveratrol in Patients with Minimal Hepatic Encephalopathy. Nutrients 2018;10:E329. [PMID: 29522439 DOI: 10.3390/nu10030329] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
90 Kronsten VT, Tranah TH, Pariante C, Shawcross DL. Gut-derived systemic inflammation as a driver of depression in chronic liver disease. J Hepatol 2021:S0168-8278(21)02180-2. [PMID: 34800610 DOI: 10.1016/j.jhep.2021.11.008] [Reference Citation Analysis]
91 Puri P, Kotwal N. An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.09.010] [Reference Citation Analysis]
92 Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2016;10:517-536. [PMID: 26633044 DOI: 10.1586/17474124.2016.1127756] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
93 Bajaj JS, O'Leary JG, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Lai J, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort. Aliment Pharmacol Ther 2019;49:1518-27. [PMID: 31032966 DOI: 10.1111/apt.15265] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
94 Harris DG. Management of pain in advanced disease. British Medical Bulletin 2014;110:117-28. [DOI: 10.1093/bmb/ldu010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
95 Louissaint J, Kassab I, Yeboah-Korang A, Fontana RJ. Combining K-72 Hepatic Failure with 15 Individual T-Codes to Identify Patients with Idiosyncratic Drug-Induced Liver Injury in the Electronic Medical Record. Dig Dis Sci 2021. [PMID: 34427818 DOI: 10.1007/s10620-021-07223-8] [Reference Citation Analysis]
96 Addolorato G, Vassallo GA, Mirijello A, Gasbarrini A. Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows. Neurotherapeutics 2020;17:127-41. [PMID: 31713188 DOI: 10.1007/s13311-019-00802-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
97 Soleimanpour H, Safari S, Shahsavari Nia K, Sanaie S, Alavian SM. Opioid Drugs in Patients With Liver Disease: A Systematic Review. Hepat Mon 2016;16:e32636. [PMID: 27257423 DOI: 10.5812/hepatmon.32636] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
98 Soleimanpour M, Imani F, Safari S, Sanaie S, Soleimanpour H, Ameli H, Alavian SM. The Role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Patients With Hepatic Disease: A Review Article. Anesth Pain Med 2016;6:e37822. [PMID: 27843779 DOI: 10.5812/aapm.37822] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
99 Pfeiffenberger J, Weiss KH, Stremmel W. Wilson disease: symptomatic liver therapy. Handb Clin Neurol 2017;142:205-9. [PMID: 28433104 DOI: 10.1016/B978-0-444-63625-6.00017-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
100 Bajaj JS, Ellwood M, Ainger T, Burroughs T, Fagan A, Gavis EA, Heuman DM, Fuchs M, John B, Wade JB. Mindfulness-Based Stress Reduction Therapy Improves Patient and Caregiver-Reported Outcomes in Cirrhosis. Clin Transl Gastroenterol 2017;8:e108. [PMID: 28749453 DOI: 10.1038/ctg.2017.38] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]